麻豆果冻传媒影音

The manufacturer of an ultrasound device to treat early prostate cancer will pursue of FDA review in an effort to get the device on the U.S. market. Last year, an FDA advisory committee turned thumbs down on a premarket approval (PMA) bid by Lyon, France-based EDAP-TMS for the Ablatherm high-intensity focused ultrasound (HIFU) device. Following discussions with the FDA, EDAP officials have decided to seek rather than the more rigorous PMA. Under the de novo approval process, the company needs only to demonstrate that its device offers a new way to remove prostate tissue, as opposed to proving its safety and efficacy in treating prostate cancer.

The University of California Los Angeles, Apple, and Sage Bionetworks have announced development of a mobile app to track five common adverse effects of breast cancer therapy: fatigue, cognitive function problems, sleep disturbance, mood changes, and reduced exercise capacity. is available free to all women (not just breast cancer survivors), ages 18 to 80, from the iTunes App Store. Information gleaned from the app's use will form to understand variability in treatment-related symptoms.

Oncology nurse , discusses the evolution of the to the recognition that everyone needs to cry sometimes, including men who have cancer.

In a preview of its second annual report to Congress, the promises a mix of "significant progress in the fight against cancer coupled with profound changes occurring in the cancer care practice landscape," leading to equally profound effects on patient care and access. Stay tuned to MedPage Today for details of the March 17 briefing.

-- people who eschew all meat except fish -- may have the upper hand against colon cancer, as compared with vegetarians. According to a longitudinal study of dietary practices of 78,000 people, those who switched from vegetarian to pescatarian diets had a .

Comment